Benzinga | Jan 18, 2021 06:03PM EST

MediciNova Received Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of ALS in Japan

MediciNova, Inc.(NASDAQ:MNOV) today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035. The allowed claims cover the combination of MN-166 (ibudilast) and riluzole for alleviating the negative effects of ALS, treating a patient diagnosed with ALS, and slowing progression of disease in a patient diagnosed with ALS. The allowed claims cover a wide range of doses and dosing regimens for both MN-166 (ibudilast) and riluzole.

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased to receive notice that this new patent will be granted. We believe it could substantially increase the potential value of MN-166 as patients are using the combination of MN-166 and riluzole in our ongoing Phase 3 clinical trial in ALS. Previously, a similar patent was granted in the U.S., the U.S. FDA granted both orphan-drug designation and fast-track designation to MN-166 for the treatment of ALS, and the European Commission granted Orphan Medicinal Product Designation to MN-166 for the treatment of ALS."